- ResMed (RMD, Financial) is set to announce its third-quarter earnings on April 23rd, with analysts projecting notable growth.
- The company has a strong track record of surpassing EPS estimates.
- Current stock analysis suggests a potential upside, backed by robust Wall Street forecasts.
ResMed (RMD) is preparing to release its third-quarter earnings results on April 23rd, after the market closes. Analysts are forecasting an earnings per share (EPS) of $2.36, marking a significant 10.8% increase compared to the same quarter last year. Revenue is projected to reach $1.28 billion, reflecting a 6.7% rise. Remarkably, ResMed has outperformed EPS expectations 88% of the time over the past two years, highlighting its strong financial performance.
Wall Street Analysts Forecast
According to the one-year price targets set by 13 analysts, ResMed Inc (RMD, Financial) has an average target price of $263.10. The forecasts range from a high estimate of $295.00 to a low of $195.00. This average target represents a promising potential upside of 22.90% from the current stock price of $214.08. For more detailed estimate data, please visit the ResMed Inc (RMD) Forecast page.
Brokerage Recommendations
The consensus recommendation from 19 brokerage firms rates ResMed Inc (RMD, Financial) with an average brokerage recommendation of 2.3, which corresponds to an "Outperform" status. This rating is based on a scale where 1 stands for Strong Buy, and 5 signifies Sell, indicating positive expectations for the stock's performance.
GuruFocus Valuation
According to GuruFocus estimates, the projected GF Value for ResMed Inc (RMD, Financial) in one year stands at $287.86. This suggests a notable upside potential of 34.46% from the current stock price of $214.08. The GF Value is an estimate of the fair value the stock should be traded at, calculated based on historical trading multiples, past business growth, and future business performance estimates. For more comprehensive data, visit the ResMed Inc (RMD) Summary page.
